<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39308778</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>More or less "modest" versus significant excess mortality due to COVID-19 deaths in Europe.</ArticleTitle><Pagination><StartPage>101060</StartPage><MedlinePgn>101060</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101060</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2024.101060</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>Joan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Servicio de Neumología, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peláez</LastName><ForeName>Adrián</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Ciencias de la Salud-HM Hospitales, Universidad Camilo José Cela, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumbreras</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departamento de Organización Industrial, Escuela Técnica Superior de Ingeniería (ICAI), Universidad Pontificia Comillas - IIT, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández</LastName><ForeName>Esteve</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tobacco Control Unit, WHO Collaborating Center for Tobacco Control, Institut Català d'Oncologia-ICO, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tobacco Control Research Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, School of Medicine and Clinical Sciences, Universitat de Barcelona, L'Hospitalet del Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ancochea</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Neumología, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><CoiStatement>JBS has received pharmaceutical company grants from 2020 to 2024 from Chiesi, GSK, Linde and Novartis via Hospital Universitario de La Princesa. Participated in speaking activities, advisory committees, and consultancies from 2020 to 2024 sponsored by Air Liquide, Almirall, AstraZeneca, Boehringer Ingelheim, CHEST, Chiesi, CNPT, ERS, FTH, Gebro, Grifols, GSK, IHME, Laminar Pharma, Linde, Lipopharma, Menarini, Mundipharma, Novartis, OMS/WHO, Pfizer, ResApp, RiRL, ROVI, SEPAR, Seqirus, WHO EUR, Takeda and Zambon. EF is partly supported by the Ministry of Universities and Research, Government of Catalonia (2021SGR00906) and acknowledges support from CERCA Programme to IDIBELL. Finally, JBS declares never, directly or indirectly, received any funding from tobacco manufacturers or their affiliates. All other authors declare there are no conflicts of interest related with this submission.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308778</ArticleId><ArticleId IdType="pmc">PMC11416502</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2024.101060</ArticleId><ArticleId IdType="pii">S2666-7762(24)00227-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pizzato M., Gerli A.G., La Vecchia C., Alicandro G. Impact of COVID-19 on total excess mortality and geographic disparities in Europe, 2020–2023: a spatio-temporal analysis. Lancet Reg Health Eur. 2024 doi: 10.1016/j.lanepe.2024.100996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2024.100996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerli A.G., Centanni S., Miozzo M.R., et al. COVID-19 mortality rates in the European Union, Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density. Minerva Med. 2020;111(4):308–314. doi: 10.23736/S0026-4806.20.06702-6. Epub 2020 Jun 2. PMID: 32491297.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0026-4806.20.06702-6</ArticleId><ArticleId IdType="pubmed">32491297</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Peláez A., Fernández E., Ancochea J. Impact of the COVID-19 pandemic in mortality due to respiratory diseases: a comparative analysis of 2021 and 2020 vs 2019 in Spain. Med Clin. 2023;161(5):192–198. doi: 10.1016/j.medcli.2023.04.020. Epub 2023 May 9. PMID: 37394353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcli.2023.04.020</ArticleId><ArticleId IdType="pmc">PMC10167373</ArticleId><ArticleId IdType="pubmed">37394353</ArticleId></ArticleIdList></Reference><Reference><Citation>Estadística de Defunciones según la Causa de Muerte Año 2023. Datos provisionales. https://www.ine.es/dyngs/Prensa/es/pEDCM2023.htm Available at:</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>